About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 606183, 10 pages
http://dx.doi.org/10.1155/2012/606183
Research Article

Different Effects of Resveratrol on Dose-Related Doxorubicin-Induced Heart and Liver Toxicity

1Medical Biology Unit, Medical University of Lublin, 20-059 Lublin, Poland
2Human Anatomy Department, Medical University of Lublin, 20-059 Lublin, Poland
3Histology and Embryology Department, Medical University of Lublin, 20-059 Lublin, Poland
4Department of Pulmonolgy, Oncology and Alergology, Medical University of Lublin, 20-059 Lublin, Poland
5Clinical Pathomorphology Department, Medical University of Lublin, 20-059 Lublin, Poland
6Department of Toxicology, Poznan University of Medical Sciences, 60-780 Poznan, Poland

Received 18 April 2012; Revised 17 October 2012; Accepted 24 October 2012

Academic Editor: R. Govindarajan

Copyright © 2012 Jaroslaw Dudka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The aim of the study was to evaluate the effect of resveratrol in doxorubicin-induced cardiac and hepatic toxicity. Doxorubicin was administered once a week throughout the period of 7 weeks with 1.0 or 2.0 mg/kg body weight or concomitantly with resveratrol (20 mg/kg of feed). Heart and liver toxicity was histologically and biochemically evaluated. Resveratrol protected from the heart lipid peroxidation caused by 1 mg doxorubicin and it sharply diminished superoxide dismutase activity. An insignificant effect of resveratrol on the lipid peroxidation level and the superoxide dismutase activity was observed in the hearts of rats administered a higher dose of doxorubicin. However, resveratrol attenuate necrosis and other cardiac histopathological changes were induced by a high dose of doxorubicin. Interestingly, it slightly intensified adverse cardiac histological changes in rats receiving a lower dose of doxorubicin. Resveratrol did not have any protective effect on the hepatic oxidative stress, while exerting a mild beneficial effect on the morphological changes caused by doxorubicin. All in all, this study has shown different effects of resveratrol on dose-related doxorubicin-induced heart and liver toxicity. Resveratrol may modulate the hepatic and cardiac effect of doxorubicin, depending on the drug dose.